Drug or treatment

Cetuximab clinical trials

• 79Clinical trials
• 2New in 30 days
• 49Countries

Newest trials

All recruiting trials (79)

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer

  In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07882888

• Cetuximab bioequivalence test in healthy men

  This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.

  Recruiting Phase 1 HC Biopharma Inc. · Haikou, Hainan · NCT07813468

• HSK42360-Na tablets with cetuximab in BRAF V600-mutant metastatic colorectal cancer

  This Phase 1/2 study tests whether HSK42360-Na tablets with cetuximab, with or without standard chemotherapy, are safe and may help people whose colorectal cancer has a BRAF V600 mutation that has spread.

  Recruiting Phase 1/2 Haisco Pharmaceutical Group Co., Ltd. · Beijing · NCT07790510

• Neoadjuvant therapy with encorafenib plus cetuximab N01 and mFOLFOX6 in locally advanced BRAF V600E-mutant colorectal cancer

  This trial tests a targeted, pre-surgery treatment to see if it improves the chance of long-term control in adults with locally advanced BRAF V600E-mutant colorectal cancer.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT07789210

• Petosemtamab plus chemotherapy vs standard chemo plus cetuximab or bevacizumab in RAS/BRAF WT colorectal cancer

  This phase 3 trial tests whether adding petosemtamab to standard chemotherapy works better than the usual chemo plus cetuximab or bevacizumab for people with recurrent, unresectable, or metastatic colorectal cancer that is KRAS/NRAS/BRAF wild type.

  Recruiting at 5 sites Phase 3 Genmab · Hot Springs, Arkansas and 4 other locations · NCT07775287

• Bevacizumab, sintilimab, cetuximab and irinotecan in refractory RAS wild-type metastatic colorectal cancer

  This trial tests whether adding sintilimab to a cetuximab and irinotecan backbone, with or without bevacizumab, helps patients with heavily pretreated metastatic colorectal cancer that has RAS wild-type tumors.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07722754

• Petosemtamab plus chemotherapy vs cetuximab plus chemotherapy in left-sided unresectable or metastatic colorectal cancer

  This trial tests whether adding petosemtamab to standard chemotherapy works better than cetuximab with chemotherapy for adults with left-sided, unresectable or metastatic colorectal cancer that is KRAS/NRAS wild-type.

  Recruiting at 12 sites Phase 3 Genmab · Hot Springs, Arkansas and 11 other locations · NCT07702032

• GFH276 with Cetuximab or chemotherapy in RAS-mutated solid tumors and PDAC

  This study tests whether GFH276 combined with cetuximab or standard chemotherapy can help adults with advanced solid tumors or pancreatic cancer that carry a RAS mutation.

  Recruiting at 10 sites Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Concord, New South Wales and 16 other locations · NCT07678593

• KRAS G12D-mutated pancreatic cancer: VS-7375 with or without cetuximab

  This study tests whether VS-7375, alone or with cetuximab, can help people with metastatic PDAC that carries the KRAS G12D mutation.

  Recruiting at 38 sites Phase 2 Verastem, Inc. · Los Angeles, California and 37 other locations · NCT07644559

• Neoadjuvant fulzerasib plus cetuximab N01 for KRAS G12C–mutated locally advanced colorectal cancer

  This trial will try a chemo-free combination of fulzerasib and cetuximab N01 before surgery in adults with KRAS G12C–mutated locally advanced colorectal cancer, including some with resectable metastases.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT07581912

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

• Short-course radiotherapy plus intensified chemotherapy and targeted therapy with immunotherapy for high-risk rectal cancer

  This trial tests whether adding targeted therapy and a PD-1 inhibitor to a short course of radiotherapy and standard chemotherapy helps high-risk pMMR/MSS rectal cancer patients, compared with the same radiotherapy and chemotherapy alone.

  Recruiting Phase 3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07549399

• BAY 3771249 for advanced colorectal cancer with KRAS G12D mutation

  This trial will test whether BAY 3771249, alone or with cetuximab, helps people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation.

  Recruiting at 6 sites Phase 1 Bayer · Phoenix, Arizona and 20 other locations · NCT07535112

• Cetuximab with PD-1 therapy plus chemotherapy vs PD-1 therapy with chemotherapy for recurrent/metastatic head and neck cancer

  This trial tests whether adding cetuximab to a PD-1 inhibitor plus chemotherapy helps people with recurrent or metastatic head and neck squamous cell cancer who aren’t candidates for curative treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07509099

• Sintilimab + ipilimumab N01 with cetuximab and dabrafenib for MSS BRAF V600E metastatic colorectal cancer

  This trial will test whether combining the immunotherapies sintilimab and ipilimumab N01 with cetuximab and dabrafenib helps people with microsatellite-stable, BRAF V600E metastatic colorectal cancer live longer or have better tumor control.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07506109

• AMT-676 combinations for advanced colorectal cancer

  This study tests AMT-676 together with standard chemotherapy and targeted therapies to see if it’s safe and effective for people with unresectable advanced colorectal cancer.

  Recruiting at 8 sites Phase 2 Multitude Therapeutics Inc. · Fuzhou, Fujian and 18 other locations · NCT07474727

• Radiation plus cetuximab vs radiation plus chemotherapy for advanced head and neck cancer patients who cannot receive cisplatin

  This trial tests whether adding cetuximab to radiation works as well as, or better than, radiation with carboplatin and paclitaxel for people with advanced head and neck cancers who can’t have cisplatin.

  Recruiting at 150 sites Phase 3 NRG Oncology · Birmingham, Alabama and 149 other locations · NCT07441681

• Continuing cetuximab after first progression for metastatic colorectal cancer

  This study will test whether keeping cetuximab while switching the chemotherapy backbone helps adults with RAS/BRAF wild‑type metastatic colorectal cancer whose disease progressed after first‑line anti‑EGFR therapy.

  Recruiting Phase 3 University of Campania Luigi Vanvitelli · Ancona and 40 other locations · NCT07389265

• Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer

  This phase 2 trial tests whether giving irinotecan with cetuximab again helps patients with metastatic colorectal cancer whose disease progressed after standard therapies, compared with the current standard third-line treatment of trifluridine/tipiracil plus bevacizumab, using blood-based molecular profiling to select

  Recruiting at 19 sites Phase 2 Gruppo Oncologico Italia Meridionale · Alessandria and 25 other locations · NCT07381764

• GFH375 combined with cetuximab or chemotherapy for KRAS G12D–mutant solid tumors

  This tests whether adding GFH375 to cetuximab or to standard chemotherapy helps people with advanced solid tumors that have a KRAS G12D mutation.

  Recruiting Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Beijing, Beijing Municipality and 3 other locations · NCT07259590

• Cetuximab beta plus fruquintinib, with or without immunotherapy, for first-line treatment of RAS/BRAF wild‑type unresectable metastatic colorectal cancer

  This trial tests whether combining cetuximab beta and fruquintinib, with or without immune checkpoint inhibitors, can control cancer as a chemotherapy‑free first‑line option for patients with RAS/BRAF wild‑type unresectable metastatic colorectal cancer.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT07257653

• AK104 plus FOLFIRI with cetuximab or bevacizumab for second-line MSS advanced colorectal cancer

  This trial tests whether adding AK104 to FOLFIRI with either cetuximab or bevacizumab helps people with MSS advanced colorectal cancer who progressed after oxaliplatin-based first-line therapy.

  Recruiting at 2 sites Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT07253896

• Calderasib (MK-1084) with or without cetuximab for advanced KRAS G12C solid tumors

  This study will test whether calderasib (MK-1084), alone or combined with cetuximab, can shrink advanced solid tumors in people whose cancers have the KRAS G12C mutation.

  Recruiting at 71 sites Phase 2 Merck Sharp & Dohme LLC · Baltimore, Maryland and 71 other locations · NCT07209111

• HCB101 combined with cetuximab or bevacizumab plus FOLFOX/FOLFIRI for advanced metastatic colorectal cancer

  This trial tries weekly HCB101 infusions together with cetuximab or bevacizumab and FOLFOX or FOLFIRI chemotherapy in adults with advanced or metastatic RAS/BRAF wild-type colorectal cancer who have progressed after prior chemotherapy.

  Recruiting Phase 1/2 Chang Gung Memorial Hospital · Taoyuan · NCT07204574

• IBI351 with cetuximab β for previously untreated advanced KRAS G12C non-small cell lung cancer

  This trial tests whether combining IBI351 with cetuximab β helps people with untreated advanced non-small cell lung cancer that has a KRAS G12C mutation.

  Recruiting at 5 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 6 other locations · NCT07198841

• Sacituzumab govitecan plus cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial will test whether combining sacituzumab govitecan with cetuximab works and is safe for people whose head and neck squamous cell cancer has returned or spread after prior immunotherapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07063212

• Amivantamab plus hyaluronidase versus cetuximab for advanced cutaneous squamous cell carcinoma in people with weakened immune systems

  This phase II trial tests whether amivantamab with hyaluronidase works better than cetuximab for people with recurrent or metastatic cutaneous squamous cell carcinoma who have a weakened immune system.

  Recruiting at 59 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 58 other locations · NCT07042295

• ctDNA-guided choice of cetuximab versus bevacizumab with trifluridine/tipiracil for RAS/BRAF wild-type metastatic colorectal cancer

  This trial tests whether a ctDNA blood test can help choose cetuximab plus trifluridine/tipiracil versus bevacizumab plus trifluridine/tipiracil for people with RAS/BRAF wild-type metastatic colorectal cancer who have progressed after prior treatments.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07012954

• Calderasib plus cetuximab and chemotherapy for KRAS G12C colorectal cancer

  This trial will test whether adding calderasib and cetuximab to mFOLFOX6 helps people with unresectable locally advanced or metastatic colorectal cancer that has a KRAS G12C mutation live longer without their cancer growing.

  Recruiting at 244 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 244 other locations · NCT06997497

• Using FOLFOX-HAIC to treat colorectal liver metastasis that can't be surgically removed

  This study is testing if a new combination of chemotherapy and targeted treatments can help people with colorectal cancer that has spread to the liver and can't be surgically removed, so they can eventually have surgery and live longer.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06988852

• Combining Cetuximab, Tislelizumab, and Chemotherapy for Advanced Head and Neck Cancer

  This study is testing a new combination of treatments for patients with advanced head and neck cancer to see if it helps them get better and possibly have surgery.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT06978829

• Combining Dabrafenib with FOLFOX and Cetuximab/Panitumumab for Metastatic Colorectal Cancer

  This study is testing if a new combination of chemotherapy and targeted treatments can help people with metastatic colorectal cancer that has a specific mutation feel better and live longer.

  Recruiting Phase 2 Blokhin's Russian Cancer Research Center · Moscow · NCT06978400

• Combining dalpicilib with cetuximab for treating resistant head and neck cancer

  This study is testing if adding dalpicilib to cetuximab can help people with tough-to-treat head and neck cancer feel better compared to just using cetuximab alone.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT06935188

• Zanzalintinib with pembrolizumab and cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial tests whether adding the oral drug zanzalintinib to pembrolizumab and cetuximab is safe and finds the best dose for adults with recurrent or metastatic head and neck squamous cell cancer.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois · NCT06912087

• Combining chemotherapy with cetuximab and avelumab for advanced head and neck cancer

  This study is testing a new treatment plan that combines chemotherapy with two medications, cetuximab and avelumab, to see if it helps people with advanced head and neck cancer live longer without their disease getting worse.

  Recruiting at 3 sites Phase 2 Gruppo Oncologico del Nord-Ovest · Cagliari, CAGLIARI and 7 other locations · NCT06869473

• Cetuximab with or without weekly paclitaxel after progression on pembrolizumab plus platinum/5‑FU for recurrent/metastatic head and neck squamous cell carcinoma

  This trial tests whether adding weekly paclitaxel to cetuximab helps people with recurrent or metastatic head and neck squamous cell carcinoma whose cancer progressed after first‑line pembrolizumab plus platinum/5‑FU.

  Recruiting at 16 sites Phase 2 Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Santiago de Compostela, A Coruña and 16 other locations · NCT06856213

• Combination treatment for advanced colorectal cancer

  This study is testing a new combination of treatments for advanced colorectal cancer to see if it can help patients live longer and feel better.

  Recruiting Phase 1/2 Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Shenzhen, Guangdong · NCT06776757

• Combining irinotecan liposomes with cetuximab and vermofenib for advanced colorectal cancer

  This study is testing if a new combination of treatments can help patients with advanced colorectal cancer, who haven't responded to previous therapies, feel better and have better outcomes.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06763029

• Comparing Amivantamab with FOLFIRI to Cetuximab/Bevacizumab with FOLFIRI for Colorectal Cancer

  This study is testing if a new treatment combining amivantamab with FOLFIRI can help people with certain types of colorectal cancer live longer and feel better compared to the standard treatment with cetuximab or bevacizumab plus FOLFIRI.

  Recruiting at 235 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 250 other locations · NCT06750094

• Combination treatment for recurrent head and neck cancer after pembrolizumab failure

  This study is testing a new combination treatment for adults with recurrent head and neck cancer who didn't respond to pembrolizumab to see if it can help them feel better and improve their health.

  Recruiting at 5 sites Phase 2 Centre Paul Strauss · Ars-Laquenexy and 4 other locations · NCT06725368

• Comparing two treatments for advanced left-sided colorectal cancer

  This study is testing whether a new drug called amivantamab combined with standard chemotherapy works better than cetuximab with the same chemotherapy for people with advanced left-sided colorectal cancer that can't be surgically removed.

  Recruiting at 233 sites Phase 3 Janssen Research & Development, LLC · Gilbert, Arizona and 238 other locations · NCT06662786

• Combining Avelumab with Standard Chemotherapy for Advanced Head and Neck Cancer

  This study is testing if adding avelumab to standard chemotherapy can help people with advanced head and neck cancer live longer and feel better.

  Recruiting Phase 2 Groupe Oncologie Radiotherapie Tete et Cou · Vandœuvre-lès-Nancy · NCT06640725

• Combination treatment for advanced colorectal cancer with BRAF V600E mutation

  This study is testing a new combination treatment for advanced colorectal cancer with a specific mutation to see if it works better than the usual treatment.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT06603376

• Combining cetuximab with pembrolizumab for advanced head and neck cancer

  This study is testing if adding cetuximab to pembrolizumab can help people with advanced head and neck cancer live longer and feel better compared to just using pembrolizumab alone.

  Recruiting at 192 sites Phase 3 National Cancer Institute (NCI) · Little Rock, Arkansas and 201 other locations · NCT06589804

• Combining cetuximab, irinotecan, and a PD-1 inhibitor for treating specific colorectal cancer

  This study is testing a new combination of treatments for patients with hard-to-treat right-sided colorectal cancer to see if it can help them when other options haven't worked.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06547203

• Second-line treatment for advanced colorectal cancer using new chemotherapy options

  This study is testing a new combination of chemotherapy drugs to see if it can help people with advanced colorectal cancer who haven't had success with their first treatment.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06540326

• Using cemiplimab and cetuximab before surgery for recurrent oral cavity cancer

  This study is testing if the drugs cemiplimab and cetuximab can help control recurrent oral cavity cancer before surgery to improve patient outcomes.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06448026

• Combination treatment for advanced colorectal cancer with specific mutations

  This study is testing a combination of three drugs to see if they can help people with advanced colorectal cancer that has specific mutations after they've already tried other treatments.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · Boston, Massachusetts and 1 other locations · NCT06412198

• Combination therapy for metastatic colorectal cancer with BRAF-V600E mutation

  This study is testing a new combination of three drugs to see if it can help people with advanced colorectal cancer that has a specific mutation feel better and live longer after their previous treatments stopped working.

  Recruiting Phase 2 Vall d'Hebron Institute of Oncology · Barcelona · NCT06411600

• Combination treatment for advanced colorectal cancer

  This study is testing a new combination of three drugs to see if it can help people with advanced colorectal cancer that hasn't responded to other treatments.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06369259

• Combination treatment for metastatic colorectal cancer

  This study is testing a combination of three drugs to see if it can help patients with certain types of metastatic colorectal cancer who have previously responded well to similar treatments.

  Recruiting Phase 2 Beijing Hospital · Beijing, Beijing Municipality · NCT06321081

• Thalidomide improves cetuximab and chemotherapy effectiveness for left colorectal cancer

  This study is testing if adding thalidomide can make cetuximab and chemotherapy work better for people with advanced left colorectal cancer that can't be surgically removed.

  Recruiting Phase 2 Xinqiao Hospital of Chongqing · Chongqing, Chongqing Municipality · NCT06279351

• Combination treatment for advanced head and neck cancer

  This study is testing a new combination treatment for people with advanced head and neck cancer to see if it can boost their immune response and help fight the disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06239220

• Evaluating a new treatment for advanced colorectal cancer with specific genetic mutations

  This study is testing a new combination treatment for people with advanced colorectal cancer that has a specific genetic mutation to see if it can help them live longer and feel better.

  Recruiting Phase 2 Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · Madrid · NCT06207656

• Treatment of advanced head and neck cancer with SIBP-03

  This study is testing a new treatment called SIBP-03 for people with advanced head and neck cancer to see if it works better than a placebo and how safe it is.

  Recruiting at 2 sites Phase 2 Shanghai Institute Of Biological Products · Shanghai, Shanghai Municipality and 1 other locations · NCT06194656

• Neoadjuvant therapy for advanced hypopharyngeal cancer

  This study is testing a new combination of immunotherapy and chemotherapy to see if it can help people with advanced hypopharyngeal cancer before they have surgery.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT06151743

• Combining ZEN003694 with standard chemotherapy for advanced colorectal cancer

  This study is testing if a new drug called ZEN003694 can safely improve the effects of standard chemotherapy for people with advanced colorectal cancer that hasn't responded to other treatments.

  Recruiting at 10 sites Phase 1 National Cancer Institute (NCI) · Costa Mesa, California and 15 other locations · NCT06102902

• Combining ficlatuzumab with cetuximab for advanced HPV-negative head and neck cancer

  This study is testing if adding a new drug called ficlatuzumab to cetuximab can help people with advanced HPV-negative head and neck cancer live longer and feel better compared to just using cetuximab with a placebo.

  Recruiting at 96 sites Phase 3 AVEO Pharmaceuticals, Inc. · Gilbert, Arizona and 111 other locations · NCT06064877

• Combining ulixertinib with cetuximab and encorafenib for advanced colorectal cancer

  This study is testing a new combination of three drugs to see if they can safely help people with advanced colorectal cancer who haven't responded to other treatments.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT05985954

• Combining cetuximab and irinotecan for treating advanced colorectal cancer

  This study is testing if combining two drugs, cetuximab and irinotecan, can help patients with advanced colorectal cancer who haven't had success with other treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05962502

• New treatment combination for advanced left-side colorectal cancer

  This study is testing a new combination of treatments for people with advanced left-side colorectal cancer to see if it helps them live longer without the cancer getting worse compared to the standard treatment.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Foshan, Guangdong and 2 other locations · NCT05959356

• Treatment for young patients with relapsed or refractory brain tumors

  This study is testing a new way to deliver cancer drugs directly to the brain tumors of young patients under 22 who have not responded to other treatments, to see if it helps them feel better.

  Recruiting Phase 1/2 University of Miami · Miami, Florida · NCT05956821

• Testing a new antibody treatment for advanced squamous cell cancers

  This study is testing a new antibody treatment combined with chemotherapy for people with advanced squamous cell cancers that haven't responded to standard therapies.

  Recruiting at 17 sites Phase 1/2 Hummingbird Bioscience · Sydney, New South Wales and 19 other locations · NCT05910827

• MRG003 vs cetuximab/methotrexate for RM-SCCHN after prior therapies

  This trial tests whether MRG003 can help people with recurrent/metastatic squamous cell carcinoma of the head and neck who have already tried PD-1 inhibitors and platinum therapy by comparing it to cetuximab plus methotrexate as a later-line treatment.

  Recruiting Phase 3 Lepu Biopharma Co., Ltd. · Shanghai, Shanghai Municipality · NCT05751512

• Oral bevacizumab-800CW and cetuximab-800CW to detect early esophageal adenocarcinoma

  This trial tests whether drinking two fluorescent tracers before an endoscopy helps doctors find early esophageal adenocarcinoma in people with Barrett's esophagus or suspected dysplasia.

  Recruiting Phase 2 University Medical Center Groningen · Groningen, Provincie Groningen · NCT05745857

• Combination treatment for localized colon or upper rectum cancer with BRAF mutation

  This study is testing a combination treatment of encorafenib and cetuximab for patients with localized colon or upper rectal cancer that has a specific BRAF mutation to see if it helps before surgery.

  Recruiting Phase 2 Federation Francophone de Cancerologie Digestive · Paris · NCT05706779

• Combination treatment of Penpulimab and Cetuximab for advanced head and neck cancer

  This study is testing a new combination of two medications, Penpulimab and Cetuximab, to see if they can help people with advanced head and neck cancer who haven't had treatment before.

  Recruiting at 2 sites Phase 2 Eye & ENT Hospital of Fudan University · Changchun, Jilin and 1 other locations · NCT05260671

• Combination treatment for HER2 positive metastatic colorectal cancer

  This study is testing a new combination of tucatinib, trastuzumab, and mFOLFOX6 to see if it helps people with HER2 positive metastatic colorectal cancer more than the usual treatments.

  Recruiting at 298 sites Phase 3 Seagen Inc. · Glendale, Arizona and 365 other locations · NCT05253651

• Combining palbociclib and cetuximab for advanced head and neck cancer treatment

  This study is testing if combining two drugs, palbociclib and cetuximab, can help people with advanced head and neck cancer live longer compared to using cetuximab alone.

  Recruiting at 3 sites Phase 3 Washington University School of Medicine · Worthington, Minnesota and 4 other locations · NCT04966481

• Treatment for elderly patients with advanced head and neck cancer using a new drug and radiation

  This study is testing a new drug combined with radiation to see if it helps elderly patients with advanced head and neck cancer feel better compared to just radiation or radiation with another drug.

  Recruiting at 134 sites Phase 3 Johnson & Johnson Enterprise Innovation Inc. · Birmingham, Alabama and 195 other locations · NCT04892173

• Combining chemotherapy and immunotherapy for head and neck cancer treatment

  This study is testing if combining chemotherapy with immunotherapy drugs can help people with head and neck cancer before surgery and possibly reduce the need for radiation therapy afterward.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT04722523

• Treatment for colorectal cancer patients with liver metastases that can't be surgically removed

  This study is testing two different treatment combinations to see which one helps colorectal cancer patients with liver tumors that can’t be removed by surgery live longer and possibly make their tumors operable.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT04687631

• Investigation of Encorafenib and Cetuximab for BRAF-mutated Metastatic Colorectal Cancer

  This study is testing if the combination of encorafenib and cetuximab can help people with advanced colorectal cancer that has a specific genetic mutation feel better and live longer after other treatments.

  Recruiting at 70 sites Pierre Fabre Pharma GmbH · Braunau am Inn, Upper Austria and 69 other locations · NCT04673955

• Cetuximab treatment for advanced head and neck cancer after immunotherapy

  This study is testing if the drug Cetuximab can help people with advanced head and neck cancer who didn’t respond to or couldn’t tolerate previous immunotherapy treatments.

  Recruiting Phase 2 Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT04375384

• Treatment for Stage IV Colorectal Cancer with Folfiri and Cetuximab

  This study is testing if a combination of Folfiri and Cetuximab can help people with stage IV colorectal cancer who have a specific gene type feel better and improve their treatment results.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples · NCT03874026

• Treatment of newly diagnosed glioblastoma using targeted drug infusion

  This study is testing a new way to deliver a targeted drug directly to the brain tumor in people with newly diagnosed glioblastoma to see if it can improve their treatment outcomes.

  Recruiting Phase 1/2 Northwell Health · New York, New York · NCT02861898

• Targeting brain tumors with a specific drug infusion and re-irradiation

  This study is testing a new way to deliver a drug directly to brain tumors in patients with certain aggressive types of glioblastoma to see if it can improve treatment results.

  Recruiting Phase 2 Northwell Health · New York, New York · NCT02800486

• Comparing chemotherapy combinations for advanced head and neck cancer

  This study is testing two different chemotherapy combinations to see which one works better for people with advanced head and neck cancer while they also receive radiation therapy.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT02128906

Quick answers

How many clinical trials of Cetuximab are recruiting right now?

79, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 49 countries. The most sites are in China (41 trials), United States (29 trials), Spain (12 trials), Italy (11 trials), France (10 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 46, Phase 3: 16, Phase 1/2: 10, Phase 1: 6. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →